These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 24970389

  • 1. Boolean ErbB network reconstructions and perturbation simulations reveal individual drug response in different breast cancer cell lines.
    von der Heyde S, Bender C, Henjes F, Sonntag J, Korf U, Beißbarth T.
    BMC Syst Biol; 2014 Jun 25; 8():75. PubMed ID: 24970389
    [Abstract] [Full Text] [Related]

  • 2. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
    Weingaertner IR, Koutnik S, Ammer H.
    PLoS One; 2013 Jun 25; 8(1):e53510. PubMed ID: 23308242
    [Abstract] [Full Text] [Related]

  • 3. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
    Ghayad SE, Vendrell JA, Ben Larbi S, Dumontet C, Bieche I, Cohen PA.
    Int J Cancer; 2010 Jan 15; 126(2):545-62. PubMed ID: 19609946
    [Abstract] [Full Text] [Related]

  • 4. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S, Breindl S, Buchholz S, Ortmann O, Brockhoff G.
    Cytometry A; 2011 Sep 15; 79(9):684-93. PubMed ID: 21786419
    [Abstract] [Full Text] [Related]

  • 5. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F, Rateitschak K, Kossow C, Wolkenhauer O, Jaster R.
    World J Gastroenterol; 2012 Nov 21; 18(43):6226-34. PubMed ID: 23180942
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.
    Mol Cancer Ther; 2010 Jun 21; 9(6):1489-502. PubMed ID: 20501798
    [Abstract] [Full Text] [Related]

  • 8. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH, Xue A, Julovi SM, Pavlakis N, Samra JS, Hugh TJ, Gill AJ, Peters L, Baxter RC, Smith RC.
    Clin Cancer Res; 2014 Aug 01; 20(15):4047-58. PubMed ID: 24895459
    [Abstract] [Full Text] [Related]

  • 9. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
    Yao E, Zhou W, Lee-Hoeflich ST, Truong T, Haverty PM, Eastham-Anderson J, Lewin-Koh N, Gunter B, Belvin M, Murray LJ, Friedman LS, Sliwkowski MX, Hoeflich KP.
    Clin Cancer Res; 2009 Jun 15; 15(12):4147-56. PubMed ID: 19509167
    [Abstract] [Full Text] [Related]

  • 10. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines.
    Holland WS, Chinn DC, Lara PN, Gandara DR, Mack PC.
    J Cancer Res Clin Oncol; 2015 Apr 15; 141(4):615-26. PubMed ID: 25323938
    [Abstract] [Full Text] [Related]

  • 11. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN, Andriu A, Smith TA.
    Breast Cancer Res Treat; 2014 Apr 15; 144(2):241-8. PubMed ID: 24522376
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M, Gründker C, Fister S, Kubin J, Wilkens L, Mueller MD, Hemmerlein B, Emons G, Günthert AR.
    Int J Oncol; 2012 Nov 15; 41(5):1845-54. PubMed ID: 22922893
    [Abstract] [Full Text] [Related]

  • 13. The receptor tyrosine kinase inhibitor vandetanib activates Akt and increases side population in a salivary gland tumor cell line (A253).
    Fujishiro Y, Tonogi M, Ochiai H, Matsuzaka K, Yamane GY, Azuma T.
    Int J Oncol; 2012 Jul 15; 41(1):362-8. PubMed ID: 22576692
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells.
    Bezler M, Hengstler JG, Ullrich A.
    Mol Oncol; 2012 Oct 15; 6(5):516-29. PubMed ID: 22841590
    [Abstract] [Full Text] [Related]

  • 15. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
    D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.
    Breast Cancer Res Treat; 2010 Sep 15; 123(2):387-96. PubMed ID: 19946741
    [Abstract] [Full Text] [Related]

  • 16. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
    Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S.
    Ann Oncol; 2002 Jan 15; 13(1):65-72. PubMed ID: 11863114
    [Abstract] [Full Text] [Related]

  • 17. Features of the reversible sensitivity-resistance transition in PI3K/PTEN/AKT signalling network after HER2 inhibition.
    Goltsov A, Faratian D, Langdon SP, Mullen P, Harrison DJ, Bown J.
    Cell Signal; 2012 Feb 15; 24(2):493-504. PubMed ID: 21996585
    [Abstract] [Full Text] [Related]

  • 18. Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance.
    Sahin O, Fröhlich H, Löbke C, Korf U, Burmester S, Majety M, Mattern J, Schupp I, Chaouiya C, Thieffry D, Poustka A, Wiemann S, Beissbarth T, Arlt D.
    BMC Syst Biol; 2009 Jan 01; 3():1. PubMed ID: 19118495
    [Abstract] [Full Text] [Related]

  • 19. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
    O'Brien NA, McDonald K, Tong L, von Euw E, Kalous O, Conklin D, Hurvitz SA, di Tomaso E, Schnell C, Linnartz R, Finn RS, Hirawat S, Slamon DJ.
    Clin Cancer Res; 2014 Jul 01; 20(13):3507-20. PubMed ID: 24879796
    [Abstract] [Full Text] [Related]

  • 20. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C, Vincent JP, Tang E, Dudley P, James NH, Klinowska T, Davies BR.
    Int J Oncol; 2015 Aug 01; 47(2):446-54. PubMed ID: 26095475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.